February 14, 2019

Nemus Bioscience Signs Agreement with Pharmaceuticals International Inc. to Develop Dosage Formulation for Human Dosing with NB1111 for Glaucoma

Long Beach, CA, Feb. 14, 2019 (GLOBE NEWSWIRE) -- via NEWMEDIAWIRE -- Nemus Bioscience, Inc. (OTCQB: NMUS), a biopharmaceutical company focused on bioengineered cannabinoid-based therapeutics to address global medical indications, announced today that it has signed an agreement with Pharmaceuticals International Inc. (Pii), a contract development manufacturing organization (CDMO) to develop a sterile eyedrop dosage formulation of NB1111 for human dosing. NB1111 is Nemus' proprietary prodrug of tetrahydrocannabinol (THC) that is currently undergoing development for the treatment of glaucoma.

"Pii is an experienced formulator of ocular-based therapies and we look forward to working with them, and our discovery and research colleagues at the University of Mississippi, to advance a clinical-grade formulation of NB1111 into the clinic," noted Brian Murphy, MD, CEO and Chief Medical Officer of Nemus. "The Company plans to conduct a first-in-human, single-ascending dose clinical trial in Australia among patients with mild to moderate glaucoma."

"We look forward to partnering with Nemus to develop an ophthalmic formulation of NB1111 as an improved treatment option for patients with glaucoma. Pii's extensive product development expertise will be an invaluable contributor to ensuring on-time delivery of the NB1111 formulation for evaluation in the planned clinical trial," added Dr. Kurt Nielsen, Pii's President and CEO.

About Pharmaceutics International, Inc.
Pii is a privately held CDMO providing dosage form development and cGMP manufacturing services to the global pharmaceutical industry. Headquartered in Hunt Valley, Maryland, USA, Pii's services include pre-formulation development, and clinical and commercial cGMP manufacturing of parenterals, liquid solutions and oral solids, including soft gels, tablets and capsules. In addition, the Company offers containment suites to handle potent drugs and Schedules I-V controlled substances.

For more information, please visit www.pharm-int.com.

About Nemus Bioscience, Inc.
The Company is a biopharmaceutical company, headquartered in Long Beach, California, focused on the discovery, development, and commercialization of bioengineered cannabinoid-based therapeutics for significant unmet medical needs in global markets. With

proprietary technology licensed from the University of Mississippi, Nemus is developing novel ways to deliver cannabinoid-based drugs for specific indications with the aim of optimizing the clinical effects of such drugs while limiting potential adverse events. Nemus' strategy is to explore the use of proprietary biosynthetic compounds, alone or in combination with corporate partners.

Nemus is part of the Emerald Health group, which represents a broad array of companies focused on developing pharmaceutical, botanical, and nutraceutical products developed to provide wellness and medical benefits by interacting with the human body's endocannabinoid system.

For more information, visit www.nemusbioscience.com.

CONTACT

Nemus Investor Relations
PCG Advisory Group
Adam Holdsworth
Email: adamh@pcgadvisory.com
Phone: 646-862-4607

Doug Cesario
Chief Financial Officer
Email: doug@nemusbio.com
Phone: 949-336-3437

FORWARD LOOKING STATEMENTS

This press release contains forward-looking statements, including statements regarding our product development, business strategy, product milestones, EHS commitment to purchase shares in the open market, timing of clinical trials and commercialization of cannabinoid-based therapeutics. Such statements and other statements in this press release that are not descriptions of historical facts are forward-looking statements that are based on management's current expectations and assumptions and are subject to risks and uncertainties. If such risks or uncertainties materialize or such assumptions prove incorrect, our business, operating results, financial condition and stock price could be materially negatively affected. In some cases, forward-looking statements can be identified by terminology including "anticipated," "contemplates," "goal," "focus," "aims," "intends," "believes," "can," "could," "challenge," "predictable," "will," "would," "may" or the negative of these terms or other comparable terminology. We operate in a rapidly changing environment and new risks emerge from time to time. As a result, it is not possible for our management to predict all risks, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements the Nemus may make. Risks and uncertainties that may cause actual results to differ materially include, among others, our capital resources, uncertainty regarding the results of future testing and development efforts and other risks that are described in the Risk Factors section of Nemus' most recent annual or quarterly report filed with the Securities and Exchange Commission. Except as expressly required by law, Nemus disclaims any intent or obligation to update these forward-looking statements.

This news release shall not constitute an offer to sell, or the solicitation of an offer to buy,

any securities, nor shall there be any sales of securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such jurisdiction. Any securities that may be offered in the United States will be offered only to accredited investors pursuant to Regulation D of the Securities Act.

Source: Nemus Bioscience, Inc.